



Hikma Pharmaceuticals PLC – Results of Annual General Meeting

LONDON, 6 June 2007 – Hikma Pharmaceuticals PLC (“the Company”) advises that at its Annual General Meeting of shareholders, held at the London Underwriting Centre, that began at 11.00am today, 6 June 2007, resolutions 1 to 8 and resolution 10 contained in the Notice of Annual General Meeting were passed as ordinary resolutions on a show of hands. Resolution 9 was passed as a special resolution on a show of hands and resolution 11 was passed as an ordinary resolution by way of a poll. The results of the poll are set out below:

| Resolution 11 | For | Against |
|--|------------|----------------|
| Waiver of Rule 9 of the City Code on Takeovers and Mergers | 39,201,592 | 2,150,591 |

Copies of the resolutions dealing with special business passed at the Annual General Meeting have been submitted to the UK Listing Authority for publication through the Listing Authority’s Document and Viewing Facility.

The total number of proxies received for each resolution is set out below.

| Resolutions | For | Against | Vote withheld |
|--|------------|----------------|----------------------|
| 1 Receipt of accounts, together with reports of the Directors and auditors | 45,853,772 | 0 | 31,478 |
| 2 Declaration of final dividend | 45,885,250 | 0 | 0 |
| 3 Reappointment of Dr Ronald Goode as a Director of the Company | 43,532,532 | 2,076,718 | 276,000 |
| 4 Reappointment of Deloitte & Touche as auditors of the Company | 45,685,600 | 96,000 | 103,650 |
| 5 Authorise the Directors to set the remuneration of the auditors | 45,885,200 | 0 | 50 |
| 6 Approval of the Board report on remuneration | 43,435,722 | 2,172,718 | 276,810 |
| 7 Approval of electronic communications | 45,885,250 | 0 | 0 |
| 8 Authorise the Directors to allot relevant securities up to an aggregate nominal amount of £5,637,913 | 45,883,490 | 1,000 | 760 |
| 9 Empower the Directors to allot equity securities for cash on a non pre-emptive basis up to an aggregate nominal amount of £845,687 | 45,884,250 | 1,000 | 0 |

| | | | | |
|----|---|------------|------------|-----------|
| 10 | Authorise an increase in the maximum aggregate annual fees payable to the directors to £750,000 | 35,384,437 | 10,224,003 | 276,810 |
| 11 | Waiver of Rule 9 of the City Code on Takeovers and Mergers | 38,476,026 | 2,150,591 | 1,922,857 |

The number of 10p ordinary shares in issue on 6 June 2007 was 169,137,407.

Waiver of Rule 9 of the City Code on Takeovers and Mergers

In relation to Resolution 11, at today's date, the total number of ordinary shares held by the Concert Party, is 60,550,416, representing a combined shareholding of 35.800% of the issued share capital of the Company. Assuming that LTIP Awards are made in respect of the full number of shares referred to in the circular to shareholders dated 25 April 2007, that all such grants vest in full, that all Options currently held by members of the Concert Party were to be fully exercised and the resulting Ordinary Shares retained by the Concert Party members, the Concert Party would hold, in aggregate, interests over 62,659,557 Ordinary Shares, representing 36,590 per cent. of the issued share capital of the Company (as enlarged by the Option Exercises by members of the Concert Party and the issue of Ordinary Shares to members of the Concert Party pursuant to the LTIP Awards, but assuming no other issue of shares) versus 36.428 per cent. of the issued share capital of the Company on a similar basis, prior to the grant of such LTIP Awards.

Declaration of final dividend

The final dividend of 4.0 cents per share will be paid on 18 June 2007 to shareholders on the register on 18 May 2007. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend is 1.9330 US dollars to one Pound Sterling, equal to 2.007 pence per share. Shareholders resident in Jordan have been given the opportunity to receive the dividend in Jordanian Dinar, at a rate of 0.708 Jordanian Dinar per US dollar.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles
Company Secretary

+44 20 7399 2670

Susan Ringdal
Investor Relations Director

+44 20 7399 2670

Brunswick Group

Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: Generic, Branded and Injectable Pharmaceuticals. Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, the United States and Europe. In 2006, the Group had revenue of \$317 million and profit attributable to shareholders of \$55 million. At 31 December 2006, the Group had over 2,443 employees. For news and other information, please visit www.hikma.com.